ArQule Announces Tivantinib Meets Primary Endpoint, Significantly Extending Time to P

		Cancer Friends Network > Types of Cancer > Adrenocortical Carcinoma
ArQule Announces Tivantinib Meets Primary Endpoint, Significantly Extending Time to P

Tim Pearson

LinkBack

Thread Tools

Display Modes

#1 (permalink)

01-19-2012, 02:32 AM

cancerfr

Administrator

Join Date: Sep 2008

Posts: 47,193

ArQule Announces Tivantinib Meets Primary Endpoint, Significantly Extending Time to P

ArQule, Inc. today announced that treatment with tivantinib as single agent therapy produced a statistically significant 56 percent improvement in time-to-progressio

Tim Pearson

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts BB code is On Smilies are On [IMG] code is On HTML code is Off Trackbacks are On Pingbacks are On Refbacks are On Forum Rules

All times are GMT. The time now is 09:24 AM.